Loading…
Connect Biopharma Holdings Limited is projected to rise to $2.61 by 2027, a +29% move from its current price of $2.02. CNTB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $1.94 | $2.02 | $2.10 | +0.05% |
| Aug 5 | $1.91 | $2.02 | $2.14 | +0.10% |
| Aug 6 | $1.89 | $2.02 | $2.16 | +0.15% |
| Aug 7 | $1.87 | $2.02 | $2.19 | +0.20% |
| Aug 8 | $1.86 | $2.03 | $2.21 | +0.25% |
| Aug 9 | $1.84 | $2.03 | $2.23 | +0.31% |
| Aug 10 | $1.83 | $2.03 | $2.25 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.83 | $2.03 | $2.25 | +0.36% |
| Week 2 | $1.76 | $2.03 | $2.35 | +0.71% |
| Week 3 | $1.71 | $2.04 | $2.44 | +1.07% |
| Week 4 | $1.67 | $2.05 | $2.52 | +1.43% |
| Week 5 | $1.63 | $2.06 | $2.59 | +1.79% |
| Week 6 | $1.60 | $2.06 | $2.66 | +2.16% |
| Week 7 | $1.58 | $2.07 | $2.72 | +2.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company operating in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
The company was founded in 2012 and is headquartered in San Diego, California.
Its stock trades under the CNTB symbol and is categorized in Healthcare.
Connect Biopharma Holdings Limited (CNTB) is a healthcare company currently trading at $2.02 with a market cap of $127.19M. It is ranked 4031 by market capitalization among peers.
The current price sits within a forecasted trajectory that shows growing averages through 2030 and beyond, with a long-run path toward higher levels. The year-by-year forecast includes an average price of $2.02 in 2026 rising to $10.25 by 2050, with an implied ROI reaching 407.6% in 2050.
This outlook reflects a bullish tilt over the multi-year horizon, though near-term momentum remains cautious given a bearish technical stance in the 30-day picture.
A major floor 23.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.5% away) — a key level to hold.
The nearest ceiling, 31.7% above — a clean break opens room to run.
A major ceiling 82.7% above — clearing it would confirm fresh momentum.
Key CNTB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CNTB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.07 | Sell | $2.08 | Sell |
| MA 10 | $2.13 | Sell | $2.13 | Sell |
| MA 20 | $2.25 | Sell | $2.19 | Sell |
| MA 50 | $2.23 | Sell | $2.27 | Sell |
| MA 100 | $2.47 | Sell | $2.34 | Sell |
| MA 200 | $2.40 | Sell | $2.26 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.92 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -119.49 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -16.87 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.14 | Sell |
| Awesome (5,34) | -0.15 | Sell |
| Ultimate (7,14,28) | 25.85 | Buy |
| Momentum (10) | -0.36 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 2.03 | Sell |
| ADX (14) | 12.79 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is bearish overall, with RSI(14) at 40.
SMA50 is $2.23 and SMA200 is $2.40, indicating the shorter-term price momentum is weaker relative to longer-term averages. The stock faces a near-term resistance at $2.66 and has support at $1.99.
The 30-day range runs from $1.56 to $2.61, and volatility remains high at 70%, underscoring elevated risk in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.99 | $2.02 | $2.67 | 0% | Neutral | |
| $2.00 | $2.61 | $3.64 | +29% | Bullish | |
| $1.85 | $2.53 | $3.71 | +25% | Bullish | |
| $1.82 | $2.57 | $3.92 | +27% | Bullish | |
| $1.73 | $2.52 | $3.97 | +25% | Bullish | |
| $1.78 | $2.66 | $4.32 | +32% | Bullish | |
| $2.26 | $3.48 | $5.79 | +72% | Bullish | |
| $2.43 | $3.85 | $6.55 | +91% | Bullish | |
| $2.44 | $3.95 | $6.86 | +95% | Bullish | |
| $2.41 | $4.00 | $7.08 | +98% | Bullish | |
| $3.35 | $6.22 | $11.92 | +208% | Bullish | |
| $4.61 | $10.23 | $21.95 | +407% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.99 | $2.02 | $2.42 | +0.00% |
| September 2026 | $1.73 | $2.07 | $2.56 | +2.39% |
| October 2026 | $1.75 | $2.12 | $2.66 | +2.30% |
| November 2026 | $1.68 | $2.05 | $2.62 | -2.99% |
| December 2026 | $1.68 | $2.07 | $2.67 | +0.83% |
Click any year to see its month-by-month CNTB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CNTB price prediction for 2026 points to an average of $2.02 (low $1.99, high $2.67) — a potential gain of 0% on today's $2.02. Price action looks broadly range-bound.
In 2027, CNTB is projected to trade between $2.00 and $3.64, averaging $2.61 — a potential gain of +29% from today's $2.02. That is up +29% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Connect Biopharma Holdings Limited's 2028 outlook centres on $2.53, within a $1.85 to $3.71 range. That is -3% versus the projected 2027 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2029, CNTB could reach as high as $3.92, with a base case around $2.57 and support toward $1.82 — roughly +27% from $2.02. Buyers look set to stay in control over this stretch.
Expect CNTB to range from $1.73 to $3.97 through 2030. The $2.52 average target implies a +25% move from current prices. That is -2% versus the projected 2029 average. Momentum favours further upside here.
The CNTB price prediction for 2031 points to an average of $2.66 (low $1.78, high $4.32) — a potential gain of +32% on today's $2.02. Buyers look set to stay in control over this stretch.
In 2032, CNTB is projected to trade between $2.26 and $5.79, averaging $3.48 — a potential gain of +72% from today's $2.02. That is up +31% on the projected 2031 average. Momentum favours further upside here.
Connect Biopharma Holdings Limited's 2033 outlook centres on $3.85, within a $2.43 to $6.55 range. That is up +11% on the projected 2032 average. That marks a +91% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CNTB could reach as high as $6.86, with a base case around $3.95 and support toward $2.44 — roughly +95% from $2.02. Momentum favours further upside here.
Expect CNTB to range from $2.41 to $7.08 through 2035. The $4.00 average target implies a +98% move from current prices. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The CNTB price prediction for 2040 points to an average of $6.22 (low $3.35, high $11.92) — a potential gain of +208% on today's $2.02. Momentum favours further upside here.
In 2050, CNTB is projected to trade between $4.61 and $21.95, averaging $10.23 — a potential gain of +407% from today's $2.02. That is up +65% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CNTB today (≈ 495.049505 CNTB) could be worth
$5,066.54
+$4,066.54 (+407%) by 2050 · US Dollar
Based on the average projected CNTB price of $10.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CNTBwould be worth at today's price.
$1,000 invested in CNTB on Jul 31, 2025 (≈ 495.04951 CNTB) would be worth
$1,000
+$0 (+0.0%) today · 1.00× · US Dollar
Based on a CNTB entry price of $2.02 vs. today's $2.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.14 | $943.93 | -5.6% |
| 1 month ago | $2.39 | $845.19 | -15.5% |
| 3 months ago | $2.47 | $817.81 | -18.2% |
| 6 months ago | $2.46 | $821.14 | -17.9% |
| 1 year ago | $2.02 | $1,000 | +0.0% |
| All time (5.0y) ago | $22.75 | $88.79 | -91.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CNTB forecast.
Our base-case forecast reaches $4.00 around 2040.
Implied market cap at $4.00: $251.86M
The multi-year forecast projects a bullish trend beginning in the late 2020s, with the average price climbing from $2.61 in 2027 to higher levels through 2035 and beyond. Notably, 2030 shows an average of $2.52 with an implied growth to $3.98 as the max, and a 24.8% ROI figure in that year.
By 2040 the average is forecast at $6.21 with a 207.5% ROI, and by 2050 the average reaches $10.25 with a 407.6% ROI. The forecast also shows a sequence of rising medians from 2032 (avg $3.49) to 2033 (avg $3.85) and 2034 (avg $3.94), and 2035 (avg $4.00), all described as bullish in sentiment. While these are estimates, they illustrate potential upside against the backdrop of near-term bearish signals and high volatility.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.52 with a max of $3.98 and a min of $1.73; the implied ROI for 2030 is 24.8 and sentiment is BULLISH.
Forecasts indicate a bullish trajectory from 2027 onward, with average prices rising to $2.61 in 2027 and reaching $10.25 on average by 2050. The corresponding ROI figures include 29.2 in 2027, 24.8 in 2028, 27.2 in 2029, 24.8 in 2030, 31.6 in 2031, 72.6 in 2032, 90.5 in 2033, 95.1 in 2034, 98.3 in 2035, 207.5 in 2040, and 407.6 in 2050. These are estimates and not guarantees.
Yes, the forecast shows a max of $5.80 in 2032 and $6.55 in 2033, indicating that reaching $5 is within the projected range during that horizon.
RSI(14) is 40, SMA50 is $2.23, SMA200 is $2.40, support is at $1.99, and resistance is at $2.66. The 30-day range is $1.56 to $2.61, with annualized volatility at 70%.
The current price is $2.02 and the market cap is $127.19M. The stock is ranked 4031 by market cap.
Connect Biopharma Holdings Limited Community Discussion
0Share your Connect Biopharma Holdings Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.